DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Apokyn (Apomorphine Hydrochloride) - Summary

 
 



APOKYN SUMMARY

APOKYN™ (apomorphine hydrochloride, USP) is a non-ergoline dopamine agonist.

APOKYN™ (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease. APOKYN has been studied as an adjunct to other medications (see CLINICAL PHARMACOLOGY: Clinical Trials).


See all Apokyn indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Apokyn (Apomorphine)

Study links Parkinson's disease to gut bacteria
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2014.12.12]
A new study finds that people with Parkinson's disease have a different mix of gut bacteria to healthy counterparts, suggesting this might be useful for diagnosis or treatment.

Parkinson's disease-related weight and eating habits
Source: Depression News From Medical News Today [2014.11.25]
Patients affected by Parkinson's disease often show marked changes in body weight: they may gain or lose a lot of weight depending on the stage of the disease, or they may put on up to ten kilos...

'Medium' daily exercise tied to lower risk of Parkinson's disease
Source: Sports Medicine / Fitness News From Medical News Today [2014.11.19]
A new study finds medium amounts of daily physical exercise from doing chores, commuting and leisure pursuits is associated with a reduced risk of developing Parkinson's disease.

The inhibition of a mitochondrial fission protein shows promise as a potential treatment for Parkinson's disease
Source: Huntingtons Disease News From Medical News Today [2014.11.08]
A study led by a researcher from Plymouth University in the UK, has discovered that the inhibition of a particular mitochondrial fission protein could hold the key to potential treatment for...

Parkinson's Disease
Source: MedicineNet levodopa-carbidopa Specialty [2013.12.04]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/4/2013 12:00:00 AM

more news >>

Published Studies Related to Apokyn (Apomorphine)

Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. [2014]
may not be needed, although this has not been systematically studied... CONCLUSION: Our data suggest that trimethobenzamide helps reduce nausea/vomiting

Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease. [2014]
apomorphine rescue treatment... CONCLUSIONS: Our results indicate that a 3-month use of intermittent apomorphine

Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. [2011.01]
Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD...

Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. [2009.05]
BACKGROUND: Motor fluctuations in patients with advanced Parkinson's disease may be successfully treated with subcutaneous apomorphine infusion or intraduodenal levodopa/carbidopa infusion. No comparative trials of these two alternatives were performed. AIMS OF THE STUDY: We present a subanalysis from a randomized crossover clinical trial where levodopa infusion as monotherapy was compared with any other combination of pharmacotherapy in fluctuating patients. Four patients used apomorphine infusion and oral levodopa in the comparator arm. The results of these four patients are presented in detail... CONCLUSIONS: Monotherapy with duodenal infusion of levodopa was more efficacious and brought greater QoL than combination therapy with apomorphine infusion in these fluctuating patients.

Apomorphine nodules in Parkinson's disease: best practice considerations. [2008.10]
Apomorphine hydrochloride infusion therapy is used by approximately 1000 people with advanced Parkinson's disease in the UK (Britannia Pharmaceuticals Ltd, 2008).

more studies >>

Clinical Trials Related to Apokyn (Apomorphine)

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Recruiting]

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease [Recruiting]
The purpose of this study is to compare the effects of apomorphine, given by two different methods, to determine how best to manage dyskinesias.

Safety/Efficacy of Tigan´┐Ż to Control Nausea/Vomiting Experienced During Apokyn´┐Ż Initiation and Treatment [Recruiting]
The purposes of the study are to determine:

i. To assess the efficacy of Tigan« (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn« (apomorphine)

ii. To determine the optimal duration for continuation of Tigan« following initiation of Apokyn« therapy

iii. To assess the safety of Tigan« in combination with Apokyn«

iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated concomitantly with and without Tigan®

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease [Completed]

Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study [Completed]
Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations. We suppose that painful symptoms could be related to the neurotransmitter deficit of PD. So, we would like to evaluate the involvement of dopaminergic system in nociceptive processing in PD patients. The objectives of this study is to assess and to compare the effect of a dopamine agonist administration on the nociceptive threshold and on the cerebral activity using positrons emission tomography (PET scan) in two groups of PD patients (in 16 painful PD patients and in 16 pain free PD patients). We hypothesise that dopamine agonist could normalise nociceptive threshold and cerebral activity which were both abnormal in PD patients. Moreover, we think that painful PD patients could be more improved by dopamine agonist than pain free PD patients.

more trials >>

Reports of Suspected Apokyn (Apomorphine) Side Effects

Fall (4)Pruritus (2)Erythema (2)Somnolence (2)Malaise (2)Overdose (2)Dyspnoea (2)Condition Aggravated (2)Atrial Fibrillation (2)Malabsorption From Injection Site (2)more >>


Page last updated: 2014-12-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014